408 related articles for article (PubMed ID: 20543858)
21. Current Status of Proteomics in Ewing's Sarcoma.
Kondo T
Proteomics Clin Appl; 2019 May; 13(3):e1700130. PubMed ID: 29992772
[TBL] [Abstract][Full Text] [Related]
22. Small-molecule screen identifies modulators of EWS/FLI1 target gene expression and cell survival in Ewing's sarcoma.
Boro A; Prêtre K; Rechfeld F; Thalhammer V; Oesch S; Wachtel M; Schäfer BW; Niggli FK
Int J Cancer; 2012 Nov; 131(9):2153-64. PubMed ID: 22323082
[TBL] [Abstract][Full Text] [Related]
23. Ewing's sarcoma precursors are highly enriched in embryonic osteochondrogenic progenitors.
Tanaka M; Yamazaki Y; Kanno Y; Igarashi K; Aisaki K; Kanno J; Nakamura T
J Clin Invest; 2014 Jul; 124(7):3061-74. PubMed ID: 24911143
[TBL] [Abstract][Full Text] [Related]
24. Microsatellites as EWS/FLI response elements in Ewing's sarcoma.
Gangwal K; Sankar S; Hollenhorst PC; Kinsey M; Haroldsen SC; Shah AA; Boucher KM; Watkins WS; Jorde LB; Graves BJ; Lessnick SL
Proc Natl Acad Sci U S A; 2008 Jul; 105(29):10149-54. PubMed ID: 18626011
[TBL] [Abstract][Full Text] [Related]
25. Caveolin-1 (CAV1) is a target of EWS/FLI-1 and a key determinant of the oncogenic phenotype and tumorigenicity of Ewing's sarcoma cells.
Tirado OM; Mateo-Lozano S; Villar J; Dettin LE; Llort A; Gallego S; Ban J; Kovar H; Notario V
Cancer Res; 2006 Oct; 66(20):9937-47. PubMed ID: 17047056
[TBL] [Abstract][Full Text] [Related]
26. Transformation induced by Ewing's sarcoma associated EWS/FLI-1 is suppressed by KRAB/FLI-1.
Chan D; Wilson TJ; Xu D; Cowdery HE; Sanij E; Hertzog PJ; Kola I
Br J Cancer; 2003 Jan; 88(1):137-45. PubMed ID: 12556973
[TBL] [Abstract][Full Text] [Related]
27. Let-7a is a direct EWS-FLI-1 target implicated in Ewing's sarcoma development.
De Vito C; Riggi N; Suvà ML; Janiszewska M; Horlbeck J; Baumer K; Provero P; Stamenkovic I
PLoS One; 2011; 6(8):e23592. PubMed ID: 21853155
[TBL] [Abstract][Full Text] [Related]
28. Hsa-mir-145 is the top EWS-FLI1-repressed microRNA involved in a positive feedback loop in Ewing's sarcoma.
Ban J; Jug G; Mestdagh P; Schwentner R; Kauer M; Aryee DN; Schaefer KL; Nakatani F; Scotlandi K; Reiter M; Strunk D; Speleman F; Vandesompele J; Kovar H
Oncogene; 2011 May; 30(18):2173-80. PubMed ID: 21217773
[TBL] [Abstract][Full Text] [Related]
29. An Interaction with Ewing's Sarcoma Breakpoint Protein EWS Defines a Specific Oncogenic Mechanism of ETS Factors Rearranged in Prostate Cancer.
Kedage V; Selvaraj N; Nicholas TR; Budka JA; Plotnik JP; Jerde TJ; Hollenhorst PC
Cell Rep; 2016 Oct; 17(5):1289-1301. PubMed ID: 27783944
[TBL] [Abstract][Full Text] [Related]
30. [Ewing's tumours, genetic and cellular aspects].
Delattre O
Pathol Biol (Paris); 2008 Jul; 56(5):257-9. PubMed ID: 18485618
[TBL] [Abstract][Full Text] [Related]
31. Vascular endothelial growth factor expression is up-regulated by EWS-ETS oncoproteins and Sp1 and may represent an independent predictor of survival in Ewing's sarcoma.
Fuchs B; Inwards CY; Janknecht R
Clin Cancer Res; 2004 Feb; 10(4):1344-53. PubMed ID: 14977835
[TBL] [Abstract][Full Text] [Related]
32. GSTM4 is a microsatellite-containing EWS/FLI target involved in Ewing's sarcoma oncogenesis and therapeutic resistance.
Luo W; Gangwal K; Sankar S; Boucher KM; Thomas D; Lessnick SL
Oncogene; 2009 Nov; 28(46):4126-32. PubMed ID: 19718047
[TBL] [Abstract][Full Text] [Related]
33. Cell Cycle Deregulation in Ewing's Sarcoma Pathogenesis.
Kowalewski AA; Randall RL; Lessnick SL
Sarcoma; 2011; 2011():598704. PubMed ID: 21052502
[TBL] [Abstract][Full Text] [Related]
34. High ALDH activity identifies chemotherapy-resistant Ewing's sarcoma stem cells that retain sensitivity to EWS-FLI1 inhibition.
Awad O; Yustein JT; Shah P; Gul N; Katuri V; O'Neill A; Kong Y; Brown ML; Toretsky JA; Loeb DM
PLoS One; 2010 Nov; 5(11):e13943. PubMed ID: 21085683
[TBL] [Abstract][Full Text] [Related]
35. The Ewing's sarcoma oncoprotein EWS/FLI induces a p53-dependent growth arrest in primary human fibroblasts.
Lessnick SL; Dacwag CS; Golub TR
Cancer Cell; 2002 May; 1(4):393-401. PubMed ID: 12086853
[TBL] [Abstract][Full Text] [Related]
36. Ewing's sarcoma oncoprotein EWS-FLI1: the perfect target without a therapeutic agent.
Uren A; Toretsky JA
Future Oncol; 2005 Aug; 1(4):521-8. PubMed ID: 16556028
[TBL] [Abstract][Full Text] [Related]
37. Diagnostic value of the molecular genetic detection of the t(11;22) translocation in Ewing's tumours.
Dockhorn-Dworniczak B; Schäfer KL; Dantcheva R; Blasius S; Winkelmann W; Strehl S; Burdach S; van Valen F; Jürgens H; Böcker W
Virchows Arch; 1994; 425(2):107-12. PubMed ID: 7524975
[TBL] [Abstract][Full Text] [Related]
38. A molecular function map of Ewing's sarcoma.
Kauer M; Ban J; Kofler R; Walker B; Davis S; Meltzer P; Kovar H
PLoS One; 2009; 4(4):e5415. PubMed ID: 19404404
[TBL] [Abstract][Full Text] [Related]
39. FOXO1 is a direct target of EWS-Fli1 oncogenic fusion protein in Ewing's sarcoma cells.
Yang L; Hu HM; Zielinska-Kwiatkowska A; Chansky HA
Biochem Biophys Res Commun; 2010 Nov; 402(1):129-34. PubMed ID: 20933505
[TBL] [Abstract][Full Text] [Related]
40. The Ewing's sarcoma fusion protein, EWS-FLI, binds Runx2 and blocks osteoblast differentiation.
Li X; McGee-Lawrence ME; Decker M; Westendorf JJ
J Cell Biochem; 2010 Nov; 111(4):933-43. PubMed ID: 20665663
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
